F. Tartarin

Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors

X. Leleu, F. Guilhot, N. Sorel, 2018, Leukemia & lymphoma.

Low‐dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment‐free remission in chronic myeloid leukemia patients: Results of a retrospective study

S. Ragot, X. Leleu, A. Herbelin, 2020, Cancer.

[Cognitive-behavioral specialized units: predictive factors of readmissions within three months].

I. Merlet, S. Ragot, M. Paccalin, 2012, Geriatrie et psychologie neuropsychiatrie du vieillissement.